Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Registration Number
- NCT02233907
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to obtain further information on the tolerability and efficacy of Ventilat® metered dose inhaler in long-term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 595
Inclusion Criteria
- Patients of both genders older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
- Only patients who have not been treated with Ventilat® within the last year are to be considered for inclusion
Exclusion Criteria
- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Ventilat® metered dose inhaler
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic obstructive pulmonary disease patients Ventilat® - metered dose inhaler -
- Primary Outcome Measures
Name Time Method Change in the clinical picture up to 12 months
- Secondary Outcome Measures
Name Time Method Assessment of efficacy by patient on a 4-point scale after 12 months Assessment of efficacy by investigator on a 4-point scale after 12 months Assessment of tolerability by investigator on a 4-point scale after 12 months Assessment of tolerability by patient on a 4-point scale after 12 months Number of patients with adverse drug reactions up to 12 months